TY - JOUR
T1 - Down-regulation of the mitochondrial aspartate-glutamate carrier isoform 1 AGC1 inhibits proliferation and N-acetylaspartate synthesis in Neuro2A cells
AU - Profilo, Emanuela
AU - Peña-Altamira, Luis Emiliano
AU - Corricelli, Mariangela
AU - Castegna, Alessandra
AU - Danese, Alberto
AU - Agrimi, Gennaro
AU - Petralla, Sabrina
AU - Giannuzzi, Giulia
AU - Porcelli, Vito
AU - Sbano, Luigi
AU - Viscomi, Carlo
AU - Massenzio, Francesca
AU - Palmieri, Erika Mariana
AU - Giorgi, Carlotta
AU - Fiermonte, Giuseppe
AU - Virgili, Marco
AU - Palmieri, Luigi
AU - Zeviani, Massimo
AU - Pinton, Paolo
AU - Monti, Barbara
AU - Palmieri, Ferdinando
AU - Lasorsa, Francesco Massimo
PY - 2017/6/1
Y1 - 2017/6/1
N2 - The mitochondrial aspartate-glutamate carrier isoform 1 (AGC1) catalyzes a Ca2 +-stimulated export of aspartate to the cytosol in exchange for glutamate, and is a key component of the malate-aspartate shuttle which transfers NADH reducing equivalents from the cytosol to mitochondria. By sustaining the complete glucose oxidation, AGC1 is thought to be important in providing energy for cells, in particular in the CNS and muscle where this protein is mainly expressed. Defects in the AGC1 gene cause AGC1 deficiency, an infantile encephalopathy with delayed myelination and reduced brain N-acetylaspartate (NAA) levels, the precursor of myelin synthesis in the CNS. Here, we show that undifferentiated Neuro2A cells with down-regulated AGC1 display a significant proliferation deficit associated with reduced mitochondrial respiration, and are unable to synthesize NAA properly. In the presence of high glutamine oxidation, cells with reduced AGC1 restore cell proliferation, although oxidative stress increases and NAA synthesis deficit persists. Our data suggest that the cellular energetic deficit due to AGC1 impairment is associated with inappropriate aspartate levels to support neuronal proliferation when glutamine is not used as metabolic substrate, and we propose that delayed myelination in AGC1 deficiency patients could be attributable, at least in part, to neuronal loss combined with lack of NAA synthesis occurring during the nervous system development.
AB - The mitochondrial aspartate-glutamate carrier isoform 1 (AGC1) catalyzes a Ca2 +-stimulated export of aspartate to the cytosol in exchange for glutamate, and is a key component of the malate-aspartate shuttle which transfers NADH reducing equivalents from the cytosol to mitochondria. By sustaining the complete glucose oxidation, AGC1 is thought to be important in providing energy for cells, in particular in the CNS and muscle where this protein is mainly expressed. Defects in the AGC1 gene cause AGC1 deficiency, an infantile encephalopathy with delayed myelination and reduced brain N-acetylaspartate (NAA) levels, the precursor of myelin synthesis in the CNS. Here, we show that undifferentiated Neuro2A cells with down-regulated AGC1 display a significant proliferation deficit associated with reduced mitochondrial respiration, and are unable to synthesize NAA properly. In the presence of high glutamine oxidation, cells with reduced AGC1 restore cell proliferation, although oxidative stress increases and NAA synthesis deficit persists. Our data suggest that the cellular energetic deficit due to AGC1 impairment is associated with inappropriate aspartate levels to support neuronal proliferation when glutamine is not used as metabolic substrate, and we propose that delayed myelination in AGC1 deficiency patients could be attributable, at least in part, to neuronal loss combined with lack of NAA synthesis occurring during the nervous system development.
KW - AGC1 deficiency
KW - Brain hypomyelination
KW - Mitochondrial aspartate/glutamate carrier
KW - N-Acetylaspartate synthesis
KW - Neurodegenerative disorders
UR - http://www.scopus.com/inward/record.url?scp=85018317333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018317333&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2017.02.022
DO - 10.1016/j.bbadis.2017.02.022
M3 - Article
AN - SCOPUS:85018317333
SN - 0925-4439
VL - 1863
SP - 1422
EP - 1435
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 6
ER -